Durvalumab-Induced Diffuse Alveolar Hemorrhage: An Autopsy Case Report
Open Access
- 1 January 2020
- journal article
- research article
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 13 (2), 696-701
- https://doi.org/10.1159/000507848
Abstract
Durvalumab, a programmed cell death ligand 1 inhibitor, induces various immune-related adverse events (irAEs), including lung injury. However, diffuse alveolar hemorrhage (DAH) is a rare type of lung injury due to immune checkpoint inhibitors. A 76-year-old man with c-stage IIIA squamous cell carcinoma of the lung received maintenance durvalumab therapy after chemoradiotherapy. He developed dyspnea and malaise after 11 cycles of durvalumab. Chest computed tomography showed rapidly spreading bilateral ground-glass opacity in the lungs. We diagnosed DAH by hemosiderin-laden macrophages in bloody bronchoalveolar lavage fluid. Despite mechanical ventilation, steroids, and cyclophosphamide, he died of respiratory failure. The autopsy revealed that fresh and old bleeding areas coexisted, and neither pulmonary vasculitis nor diffuse alveolar damage was detected microscopically. Furthermore, CD3+ and CD8+ lymphocytes were observed in the lung interstitium, whereas CD20+ and CD4+ lymphocytes were scarcely detected. We report the first case of durvalumab-induced DAH. We should be alert to irAEs with DAH as a potential differential diagnosis of lung injury during durvalumab treatment.This publication has 13 references indexed in Scilit:
- Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors A Systematic Review and Meta-analysisJAMA Oncology, 2018
- Diffuse alveolar hemorrhage with pseudoprogression during nivolumab therapy in a patient with malignant melanomaThoracic Cancer, 2018
- A case of interstitial lung disease with alveolar hemorrhage induced by pembrolizumabOncoTargets and Therapy, 2018
- Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injuryLaboratory Investigation, 2018
- Goodpasture’s disease in a patient with advanced lung cancer treated with nivolumab: An autopsy case reportLung Cancer, 2018
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2017
- Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 TherapyJournal of Clinical Oncology, 2017
- Diffuse Alveolar Hemorrhage Associated with Edoxaban TherapyCase Reports in Critical Care, 2016
- Diffuse Pulmonary Hemorrhage: Clues to the DiagnosisCurrent Problems in Diagnostic Radiology, 2014
- Update on Diffuse Alveolar Hemorrhage and Pulmonary VasculitisImmunology and Allergy Clinics of North America, 2012